DexCom, Inc. $DXCM Position Decreased by Towarzystwo Funduszy Inwestycyjnych PZU SA

Posted by Brenda Bartman on Jun 15th, 2026

Towarzystwo Funduszy Inwestycyjnych PZU SA decreased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 70.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 29,992 shares of the medical device company’s stock after selling 70,093 shares during the period. DexCom comprises approximately 0.5% of Towarzystwo Funduszy Inwestycyjnych PZU SA’s portfolio, making the stock its 27th biggest holding. Towarzystwo Funduszy Inwestycyjnych PZU SA’s holdings in DexCom were worth $1,991,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in DXCM. CVA Family Office LLC boosted its position in shares of DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 147 shares in the last quarter. MCF Advisors LLC acquired a new position in shares of DexCom in the fourth quarter worth about $32,000. ORG Partners LLC boosted its holdings in shares of DexCom by 124.3% in the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after buying an additional 281 shares during the period. Spire Wealth Management boosted its holdings in shares of DexCom by 113.8% in the fourth quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock worth $38,000 after buying an additional 305 shares during the period. Finally, Aventura Private Wealth LLC acquired a new position in shares of DexCom in the fourth quarter worth about $43,000. Institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on DXCM shares. Raymond James Financial reiterated a “strong-buy” rating and issued a $91.00 target price on shares of DexCom in a report on Monday, June 8th. Canaccord Genuity Group set a $82.00 target price on shares of DexCom and gave the stock a “buy” rating in a report on Monday, May 18th. BTIG Research reiterated a “buy” rating and issued a $85.00 target price on shares of DexCom in a report on Monday, March 9th. Robert W. Baird set a $80.00 target price on shares of DexCom in a report on Friday, May 1st. Finally, UBS Group set a $95.00 target price on shares of DexCom in a report on Wednesday. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, DexCom currently has an average rating of “Moderate Buy” and a consensus price target of $84.29.

Check Out Our Latest Stock Report on DXCM

DexCom Stock Performance

NASDAQ:DXCM opened at $75.37 on Monday. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98. The firm has a market cap of $29.08 billion, a price-to-earnings ratio of 32.21, a P/E/G ratio of 1.18 and a beta of 1.45. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The company’s 50 day moving average is $66.13 and its 200-day moving average is $67.60.

DexCom (NASDAQ:DXCM – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same quarter last year, the firm posted $0.32 earnings per share. The company’s quarterly revenue was up 15.0% compared to the same quarter last year. Equities analysts anticipate that DexCom, Inc. will post 2.58 EPS for the current year.

Insider Activity

In other news, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the transaction, the director owned 25,007 shares of the company’s stock, valued at $1,500,670.07. This trade represents a 3.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of DexCom stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the completion of the transaction, the insider directly owned 382,482 shares in the company, valued at approximately $27,538,704. This represents a 6.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 40,994 shares of company stock worth $2,919,022. 0.28% of the stock is owned by company insiders.

About DexCom

(Free Report)

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.